950,603 Shares in AtriCure, Inc. $ATRC Acquired by Nuveen LLC

Key Points

• Nuveen LLC acquired a new stake in AtriCure, Inc., purchasing 950,603 shares valued at approximately $30.67 million, representing 1.92% of the company.
• AtriCure recently reported quarterly earnings, with $136.14 million in revenue, marking a 17.1% year-over-year increase, and exceeding consensus revenue estimates.
• Wall Street analysts have set an average price target of $50.89 for AtriCure, with ten analysts rating the stock as a "buy."

Nuveen LLC acquired a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 950,603 shares of the medical device company's stock, valued at approximately $30,666,000. Nuveen LLC owned about 1.92% of AtriCure as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Jennison Associates LLC purchased a new stake in shares of AtriCure during the 1st quarter valued at about $19,139,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of AtriCure during the 4th quarter valued at about $9,168,000. Marshall Wace LLP boosted its holdings in shares of AtriCure by 37.1% during the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after acquiring an additional 167,476 shares during the last quarter. Oberweis Asset Management Inc. purchased a new stake in shares of AtriCure during the 4th quarter valued at about $4,630,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of AtriCure by 24.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after acquiring an additional 136,015 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AtriCure

In other news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $36.00, for a total transaction of $180,000.00. Following the completion of the sale, the director directly owned 34,374 shares in the company, valued at approximately $1,237,464. This trade represents a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $36.58, for a total value of $91,450.00. Following the sale, the insider owned 71,872 shares of the company's stock, valued at approximately $2,629,077.76. This trade represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,452 shares of company stock worth $445,333. 3.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $60.00 price target on shares of AtriCure in a report on Wednesday, April 30th. UBS Group lowered their price objective on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, July 30th. Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, BTIG Research set a $54.00 price objective on shares of AtriCure in a research note on Wednesday, July 30th. Nine analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $50.89.

AtriCure Price Performance

Shares of AtriCure stock traded up $1.6150 on Friday, hitting $37.3450. 144,165 shares of the company traded hands, compared to its average volume of 582,075. The stock has a market capitalization of $1.86 billion, a P/E ratio of -48.50 and a beta of 1.61. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. AtriCure, Inc. has a 52 week low of $24.48 and a 52 week high of $43.11. The business has a 50-day simple moving average of $32.93 and a 200 day simple moving average of $33.95.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The firm had revenue of $136.14 million during the quarter, compared to analyst estimates of $130.17 million. During the same period last year, the firm posted ($0.17) earnings per share. AtriCure's revenue for the quarter was up 17.1% compared to the same quarter last year. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Research analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.